GLP1 agonists are the newest anti-obesity medication to hit the market. They were originally marketed for diabetes, but during studies were found to cause significant weight loss. There are multiple GLP1 agonists available, some of which are marketed only for diabetes, and others that are available for either diabetes or obesity. They have become increasingly popular over the past year or so which has led to multiple drug shortages.